NASDAQ : CYPH
-$0.02 (-3.25%)
%
change: 0.0 | last:
change: 0.0 | last:
change: 0.0 | last:
change: 0.0 | last:
change: 0.0 | last:
-
-
change: 0.0 | last:
-
| Filing Date | Reporting Person | Amount Beneficially Owned | % of Class |
|---|---|---|---|
| 2026-02-12 | GILEAD SCIENCES, INC. | - | 0.00% |
| 2025-11-21 | Winklevoss Capital Management, LLC | 12.08M | 19.90% |
| 2025-11-21 | Winklevoss Treasury Investments, LLC | 12.08M | 19.90% |
| 2025-11-21 | Winklevoss Capital Fund, LLC | 12.08M | 19.90% |
| 2025-11-21 | Tyler Howard Winklevoss | 12.08M | 19.90% |
| 2025-11-21 | Cameron Howard Winklevoss | 12.08M | 19.90% |
| 2025-11-18 | Severns Sean Michael | 6M | 10.59% |
| 2025-10-16 | Tyler Howard Winklevoss | 12.08M | 19.90% |
| 2025-10-16 | Cameron Howard Winklevoss | 12.08M | 19.90% |
| 2025-10-16 | Winklevoss Capital Management, LLC | 12.08M | 19.90% |
| 2025-10-16 | Winklevoss Treasury Investments, LLC | 12.08M | 19.90% |
| 2025-10-16 | Winklevoss Capital Fund, LLC | 12.08M | 19.90% |
| 2025-08-14 | Samsara BioCapital, L.P. | - | 0.00% |
| 2025-02-14 | Balyasny Asset Management L.P. | - | 0.00% |
| 2022-02-14 | HHLR Advisors, Ltd. | - | 0.00% |
| 2022-02-15 | Perceptive Advisors LLC | 8.48M | 9.60% |
| 2022-02-15 | Joseph Edelman | 8.48M | 9.60% |
| 2022-02-15 | Perceptive Life Sciences Master Fund, Ltd. | 8.48M | 9.60% |
| 2022-02-10 | Eli Lilly and Company | 3.15M | 3.50% |
| 2021-02-16 | Westend S.A. | 3M | 5.00% |
| 2021-02-16 | Artal Group S.A. | 3M | 5.00% |
| 2021-02-16 | Artal International Management S.A. | 3M | 5.00% |
| 2021-02-16 | Artal International S.C.A. | 3M | 5.00% |
| 2021-02-16 | Invus Public Equities Advisors, LLC | 3M | 5.00% |
| 2021-02-16 | Invus Public Equities, L.P. | 3M | 5.00% |
| 2021-02-16 | Stichting Administratiekantoor Westend | 3M | 5.00% |
| 2021-02-16 | Artal Treasury Limited | 3M | 5.00% |
| 2021-02-16 | Mr. Amaury Wittouck | 3M | 5.00% |
| 2020-03-23 | BeiGene, Ltd. | 9.61M | 23.70% |
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2025-12-31 | $1.16 | 66.14M | $76.72M | $14.04M | $38000 | $62.73M |
| 2024-12-31 | $2.88 | 37.55M | $108.15M | $47.25M | $266K | $61.16M |
| 2023-12-31 | $4.14 | 20.45M | $84.64M | $70.64M | $262K | $14.26M |
| 2022-12-31 | $4.50 | 11.32M | $50.96M | $20.99M | $524K | $30.49M |
| 2021-12-31 | $32.40 | 8.58M | $278.07M | $114.92M | $469K | $163.63M |
| 2020-12-31 | $22.50 | 5.93M | $133.49M | $63.83M | $776K | $70.44M |
| 2019-12-31 | $11.20 | 2.26M | $25.29M | $2.39M | $1M | $23.91M |
| 2018-12-31 | $20.00 | 1.41M | $28.29M | $16.28M | -$ | $12M |
| 2017-12-31 | $62.40 | 916.18K | $57.17M | $25.74M | -$ | $31.43M |
| 2016-12-31 | $78.60 | 939.24K | $73.82M | $793K | $30.27M | $103.31M |
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2026-06-30 | $0.61 | 176.26M | $107.92M | $7.62M | $38000 | $100.34M |
| 2026-03-31 | $0.79 | 168.1M | $133.58M | $6.69M | $38000 | $126.92M |
| 2025-12-31 | $1.16 | 66.14M | $76.72M | $14.04M | $38000 | $62.73M |
| 2025-09-30 | $0.45 | 41.44M | $18.82M | $26.76M | $3.31M | -$4.63M |
| 2025-06-30 | $0.30 | 41.44M | $12.31M | $18.13M | $39000 | -$5.79M |
| 2025-03-31 | $0.31 | 41.27M | $12.59M | $32.71M | $154K | -$19.97M |
| 2024-12-31 | $2.88 | 41.25M | $118.81M | $47.25M | $266K | $71.82M |
| 2024-09-30 | $2.57 | 41.21M | $105.91M | $62.82M | $376K | $43.46M |
| 2024-06-30 | $1.87 | 39.12M | $73.16M | $252M | $3.88M | -$174.97M |
| 2024-03-31 | $2.75 | 27.01M | $74.29M | $142.12M | $2.88M | -$64.95M |
| 2023-12-31 | $4.14 | 26.99M | $111.73M | $70.64M | $262K | $41.35M |
| 2023-09-30 | $1.38 | 26.99M | $37.24M | $80.74M | $369K | -$43.13M |